Lack of the Lysosomal Membrane Protein, GLMP, in Mice Results in Metabolic Dysregulation in Liver

Ablation of glycosylated lysosomal membrane protein (GLMP, formerly known as NCU-G1) has been shown to cause chronic liver injury which progresses into liver fibrosis in mice. Both lysosomal dysfunction and chronic liver injury can cause metabolic dysregulation. Glmpgt/gt mice (formerly known as Ncu-g1gt/gtmice) were studied between 3 weeks and 9 months of age. Body weight gain and feed efficiency of Glmpgt/gt mice were comparable to wild type siblings, only at the age of 9 months the Glmpgt/gt siblings had significantly reduced body weight. Reduced size of epididymal fat pads was accompanied by hepatosplenomegaly in Glmpgt/gt mice. Blood analysis revealed reduced levels of blood glucose, circulating triacylglycerol and non-esterified fatty acids in Glmpgt/gt mice. Increased flux of glucose, increased de novo lipogenesis and lipid accumulation were detected in Glmpgt/gt primary hepatocytes, as well as elevated triacylglycerol levels in Glmpgt/gt liver homogenates, compared to hepatocytes and liver from wild type mice. Gene expression analysis showed an increased expression of genes involved in fatty acid uptake and lipogenesis in Glmpgt/gt liver compared to wild type. Our findings are in agreement with the metabolic alterations observed in other mouse models lacking lysosomal proteins, and with alterations characteristic for advanced chronic liver injury.


Introduction
Glycosylated lysosomal membrane protein (GLMP, formerly known as NCU-G1) was first described as a nuclear protein, capable of regulating gene transcription [1]. Later studies identified GLMP as a bona fide lysosomal membrane protein [2][3][4]. The biological function of GLMP is unknown, but a high degree of conservation of the amino acid sequence indicates an important function [1]. Recently, we created and characterized a novel mouse model with no detectable expression of GLMP (Glmp gt/gt mouse, formerly known as Ncu-g1 gt/gt mouse), and showed that the predominant phenotype is chronic liver injury which had developed into a well-established fibrosis by the age of 6 months [5]. Further analyses identified accumulation of iron in Kupffer cells [5], which has been shown to be associated with metabolic dysregulation [6]. Specific accumulation of iron in Kupffer cells has been shown to correlate with the severity of metabolic liver injury [7].
Lysosomal disorders are a group of congenital metabolic disorders caused by malfunctioning of a protein related to normal lysosomal function [8][9][10][11][12][13]. Most lysosomal disorders are characterized by impaired turnover of certain metabolites, which accumulate intralysosomally and affect normal lysosome and lysosome-related processes, such as autophagy [9][10][11]. Defective recycling of macromolecules through lysosomal pathways may cause insufficient recycling of metabolites and metabolic stress [11]. In fact, metabolic irregularities have been demonstrated in several mouse models with lysosomal disorders [14].
Liver fibrosis is a result of chronic liver injury, and is characterized by capillarization of sinusoids and redirection of blood directly from the portal tract to the hepatic vein [15][16][17]. The impaired perfusion of the liver and loss of fenestrations across the endothelial cell layer contribute to the imbalance in metabolite exchange between plasma and the liver [15]. The liver is also an important organ for regulation of glucose, lipid and protein metabolism, and chronic liver injury is known to cause alterations to glucose and lipid homeostasis [18].
Using the Glmp gt/gt mouse, a mouse model lacking this lysosomal membrane protein, and characterized by chronic liver injury and liver fibrosis, we assessed the metabolic consequences of GLMP ablation, focusing on liver. and Dulbecco's phosphate-buffered saline (DPBS, with Mg 2+ and Ca 2+ ) were purchased from Life-Technologies (Carlsbad, CA, US). HEPES, L-carnitine, oleic acid (OA), glucose, bovine serum albumin (BSA), Triton X-100, sodium dodecyl sulfate (SDS) and protease inhibitor cocktail were from Sigma-Aldrich (St. Louis, MO, US). Sodium chloride and Tris Base were from VWR (Radnor, PA, US). Corning CellBIND tissue culture plates (12-well and 96-well plates) were obtained from Corning Life-Sciences (Schiphol-Rijk, The Netherlands). OptiPhase Supermix and UniFilter-96 GF/B were obtained from PerkinElmer (Shelton, CT, US). Thin layer chromatography plates were purchased from Merck (Darmstadt, Germany). Accu-Chek Aviva Nano Blood Glucose Meter System was purchased from Roche Applied Science (Mannheim, Germany). RNeasy Plus kit was obtained from Qiagen (Hilden, Germany). Brilliant III Ultra Fast SYBR Green qPCR Master Mix was obtained from Agilent Technologies (Santa Clara, CA, US) and LightCycler 480 SYBR Green I Master Mix was purchased from Roche Applied Science. Primers were designed and purchased from DNA Technology (Risskov, Denmark) and Life Technologies. Hypnorm was from VetaPharma (Leeds, UK). Midazolam was from Actavis (Parsippany, NJ, US). Animal diets were purchased from Scanbur (Karlslunde, Denmark). Protein assay reagent was purchased from Bio-Rad (Bio-Rad, Hercules, CA, US) and the content of proteins was determined using the Coomassie reagent [19]. All other chemicals used in this study were of standard commercial high-purity quality.

Animal experiments
All animal experiments were reviewed and approved by the Norwegian Animal Research Authority, and performed according to national laws and regulations. Wild type (WT) and Glmp gt/gt mice [5] were housed in an approved animal facility with access to standard rodent chow and water ad libitum unless otherwise stated. Mice were 3 weeks old at the beginning of the feeding experiment. The body weight and food intake of a total of 27 male WT and 31 male Glmp gt/gt mice, housed in 12 different cages, and a total of 13 female WT and 20 female Glmp gt/gt mice, housed in 7 different cages were monitored at intervals of 7 days for 12 weeks, and then at 2, 3.5, 4.5, 6, 7.5 and 9 months of age. Feed efficiency was calculated as the ratio between body weight gain/week for each individual mouse and the average feed intake/mouse. Biological samples were collected at designated age points (1, 2, 3.5, 6, 7.5, and 9 months). Blood was obtained from randomly fed mice through cardiac puncture, and sera were collected after coagulation and centrifugation at 1500 x g for 20 minutes. Liver, spleen and epididymal fat pads (representing visceral adipose tissue) were dissected at selected time points, weighed and frozen in liquid nitrogen. The axillary and inguinal fat depots (representing subcutaneous adipose tissue) and interscapular brown adipose tissue were inspected at 1 and 4.5 months of age. All biological samples were stored at -80°C until further analysis.

Resting blood glucose and serum and liver lipid levels
Resting blood glucose levels were measured in male WT and Glmp gt/gt mice (age = 5 months) fed ad libitum using Accu-Chek Aviva Nano Blood Glucose Meter System. Serum levels of non-esterified fatty acids (NEFA) were analyzed using NEFA-kit according to the supplier´s protocol (ILS Laboratories Scandinavia AS, Oslo, Norway). Triacylglycerol (TAG) was quantified in serum and whole liver homogenates using TG PAP 150-kit (BioMerieux, Marcy l'Etoile, France) according to the supplier's protocol.

Isolation of primary hepatocytes
Isolation of primary hepatocytes from WT and Glmp gt/gt mice (age = 4-5 weeks) was carried out by a two-step perfusion method as described [20]. Liver parenchymal and non-parenchymal cells were separated by differential centrifugation as described elsewhere [21]. Primary hepatocyte preparations with high viability (> 95%) were used in further studies.

Uptake and oxidation of oleic acid and glucose
Determination of [ 14 C]oleic acid (OA) or [ 14 C]glucose uptake and oxidation has been described previously [22]. Primary hepatocytes were isolated as described above, and cultured in hepatocyte growth medium (DMEM high glucose, enriched with 20% FBS, Pen-Strep and Fungizone) on a 96-well microplate (80.000 cells/well) (Corning CellBIND). For measurements of OA or glucose uptake and oxidation, the growth medium was removed after 24 h and the cells were exposed to [ 14 C]OA (0.5 μCi/mL, 100 μM) bound to BSA (40 μM) at a ratio of 2.5:1 in DPBS (with Mg 2+ and Ca 2+ ) with HEPES (10 mM), L-carnitine (1 mM) for 4 h or [ 14 C]glucose (0.6 μCi/mL, 200 μM) in DPBS (with Mg 2+ and Ca 2+ ) with HEPES (10 mM), L-carnitine (1 mM) and BSA (7.2 μM) for 4 h. [ 14 C]CO 2 production and total uptake of OA or glucose (sum of CO 2 and cell-associated radioactivity) were calculated using cell protein levels for standardization as described previously [22].

Thin layer chromatography
Primary hepatocytes were isolated as described above, and cultured in hepatocyte growth medium in 12-well microplates (200.000 cells/well) (Corning CellBIND). The growth medium was removed after 24 h and the cells were exposed either to fatty acid medium, consisting of [ 14 C]OA (0.5 μCi/mL, 100 μM) bound to BSA (40 μM) at a ratio of 2.5:1 in DPBS with HEPES (10 mM) and L-carnitine (1 mM) for 4 h, or to lipogenesis medium, consisting of [ 14 C]acetate (0.5 μCi/mL, 100 μM) in DMEM enriched with glucose (5.5 mM) and BSA (10 μM) for 4 h. The media were collected and stored at -20°C until further analysis, and the remaining cells washed 3x with PBS before adding 250 μL H 2 O for cell lysis and solubilized cells were stored at -20°C. Cell-associated lipids were extracted with chloroform:methanol according to Folch et al. [23] and separated by thin layer chromatography as previously described [23]. The content of radiolabelled lipids was normalized against cell protein content.

Analysis of gene expression
RNA extractions from mouse liver were carried out according to the manufacturer using RNeasy Plus kit. The expression of selected mRNA transcripts (S1 Table) was analyzed by qPCR using a LightCycler 480 (Roche Diagnostics, Manheim, Germany). PCR efficiencies were experimentally determined for each primer pair. Relative gene expression was calculated using the ΔΔCt-method, with Beta-actin and Eukaryotic translation elongation factor 2 as reference genes.

Statistical methods
All results are expressed as mean ± SEM. Linear mixed models (LMM) were used to analyze overall differences in liver/body weight ratio, spleen/body weight ratio, serum TAG and serum NEFA levels, using IBM SPSS software (SPSS Inc. Chicago, IL, US). Other data were analyzed using two-tailed T-test (SigmaPlot, Systat Software Inc, Chicago, IL, US).

Confirmation of GLMP ablation in Glmp gt/gt mice
In agreement with our previous report, analysis of lysosome-enriched fractions from mouse liver and kidneys after tyloxapol treatment [3] confirmed the lack of GLMP expression in Glmp gt/gt mice (S1 Fig).
Similar body weight gain and feed intake in WT and Glmp gt/gt mice Development of body weight in wild type (WT) and Glmp gt/gt mice was monitored from 3 weeks of age. As shown in Fig 1A, the body weight gains were similar for male WT and Glmp gt/gt mice up to the age of 7.5 months, but the Glmp gt/gt siblings were outgrown by WT mice at the age of 9 months. The feed efficiency was indistinguishable between the genotypes up to the age of 14 weeks (Fig 1B). Similar data were also obtained for female mice (data not shown).

Smaller epididymal fat pads and overall hepatosplenomegaly in Glmp gt/gt mice
In spite of similar body weight, the Glmp gt/gt mice appeared leaner compared to the WT. Male WT and Glmp gt/gt mice were sacrificed at the age of one and 4.5 months, and their epididymal fat pads/body weight ratios were determined. As shown in Fig 2A and 2B, Glmp gt/gt mice had significantly smaller epididymal fat pads compared to WT at the age of one month, with an increased difference at 4.5 months of age. In contrast, the axillary and inguinal fat depots and the interscapular brown adipose tissue were comparable betweent he genotypes (data not shown). Next, we assessed the liver/body weight and spleen/body weight ratios in WT and Glmp gt/gt mice. The Glmp gt/gt liver was significantly enlarged at 0.8, 1, 2, 4.5 and 7.5 months of age compared to age-matched WT (Fig 2C), while Glmp gt/gt spleen was significantly enlarged at 1, 2, 3.5, 4.5, 6, 7.5 and 9 months of age compared to age-matched WT animals ( Fig 2D).
Decreased blood glucose, serum lipids and increased liver triacylglycerol (TAG) in Glmp gt/gt mice Five months old Glmp gt/gt mice had significantly reduced levels of blood glucose compared to WT mice when fed ad libitum (Fig 3A). Analysis of serum concentrations of triacylglycerol (TAG) in WT and Glmp gt/gt mice aged 1-9 months, showed an overall level that was significantly lower in the Glmp gt/gt mice (p < 0.001) (Fig 3B and 3C). A significant decrease was also found for serum non-esterified fatty acids (NEFA) concentrations in Glmp gt/gt compared to WT mice aged 1-9 months (p < 0.001) (Fig 3D and 3E). Liver content of TAG was measured in 6 months old WT and Glmp gt/gt mice. As shown in Fig 3F, there were significantly higher levels of liver TAG in Glmp gt/gt compared to WT mice.

Changes in expression of metabolic genes in Glmp gt/gt liver
Metabolic homeostasis is regulated by peroxisome proliferator-activated receptors (PPARs) [24]. In livers from 3.5 months old mice, GLMP ablation resulted in altered mRNA expression of the three PPAR isoforms. Fig 4A shows a decreased expression of Ppara and increased expression of Ppard and Pparg in Glmp gt/gt liver relative to WT animals. In contrast, the PPAR co-regulator Pgc1a was not differently expressed between the two genotypes. Genes involved in de novo lipogenesis (Fasn, Scd1 and Scd2) were found to be significantly upregulated in Glmp gt/gt relative to WT liver (Fig 4B). The fatty acid transporter, Cd36 showed a 4.6-fold increased expression in Glmp gt/gt liver, while cytoplasmic fatty acid binding protein Fabp1 was significantly decreased compared to WT (Fig 4C). The expression of the initiator of peroxisomal fatty acid beta-oxidation, Acox1 was significantly decreased in Glmp gt/gt liver, while no differences were found for the expression of Acox2 (Fig 4D). Genes involved in mitochondrial fatty acid beta-oxidation (Cpt1a and Acadl) were not differently expressed between the two genotypes ( Fig 4E). Furthermore, the expression of the lipid droplet associated proteins perilipin 2 and 5 (Plin2 and Plin5) was significantly decreased in Glmp gt/gt liver (Fig 4F). A decreased expression of a lipoprotein lipase regulator, Angptl4 was also detected in Glmp gt/gt liver, while the expression of Apoc3, a very low-density lipoprotein (VLDL) regulatory protein, was increased compared to WT ( Fig  4G). With regard to genes involved in glucose metabolism, a decreased expression of the glucose transporter, Glut2 was detected in Glmp gt/gt liver compared to WT. No differences in expression were detected for liver specific hexokinase (Gck), while the expression of Pdk4, an inhibitor of pyruvate dehydrogenase complex, was significantly upregulated in Glmp gt/gt liver compared to WT (Fig 4H). Altered glucose and fatty acid uptake and oxidation in Glmp gt/gt hepatocytes To assess whether GLMP ablation affects glucose and fatty acid metabolism in liver cells, hepatocytes were isolated from 4-6 weeks old Glmp gt/gt and WT mouse liver and exposed to either [ 14 C]glucose or [ 14 C]oleic acid (OA) for 4 h. Ablation of GLMP resulted in increased glucose uptake ( Fig 5A) and oxidation (Fig 5B) in Glmp gt/gt hepatocytes. Exposure to [ 14 C]OA revealed a significantly higher uptake of [ 14 C]OA in Glmp gt/gt hepatocytes compared to WT cells ( Fig  5C), while the oxidation capacity for OA was comparable between the two genotypes ( Fig 5D).
To further explore metabolism of OA, we performed thin layer chromatography on cell culture media and cell homogenates after 4 h exposure to [ 14 C]OA. No significant difference in secretion of triacylglycerol (TAG) into the media could be detected (data not shown), but there was a significant increase of accumulated total lipids in Glmp gt/gt hepatocytes compared to WT hepatocytes (Fig 6A). This difference was primarily contributed to by a significant increase in TAG accumulation (Fig 6B). Incorporation of labelled OA in other lipids assayed, diacylglycerol (DAG) (Fig 6C), non-esterified fatty acids (NEFA) (Fig 6D), phospholipids (Fig 6E), and cholesterol esters (CE) (Fig 6F) did not significantly differ between Glmp gt/gt and WT hepatocytes. Increased de novo lipogenesis in Glmp gt/gt hepatocytes Primary hepatocytes from WT and Glmp gt/gt mice were exposed to [ 14 C]acetate for 4 h, and thin layer chromatography was performed on cell homogenates in order to assess de novo lipogenesis. The levels of newly synthesized NEFA showed no significant difference between the two genotypes (Fig 7A), but the incorporation into DAG was found to be significantly elevated (Fig 7B). A clear tendency for increased synthesis of TAG was also observed for Glmp gt/gt hepatocytes (Fig 7C), which, however, did not reach statistical significance. Higher incorporation of labelled acetate into PL ( Fig 7D) and CE (Fig 7E) was also detected in Glmp gt/gt hepatocytes. Taken together, these results indicate increased lipogenesis in Glmp gt/gt hepatocytes compared to WT cells, which was also reflected in the total amount of synthesized lipids (Fig 7F).

Discussion
In this study, we showed that wild type (WT) and Glmp gt/gt mice initially had similar growth rates. The feed efficiency was also comparable for the two genotypes up to the age of 14 weeks. Yet the epididymal fat pads were significantly smaller in Glmp gt/gt siblings compared to WT mice at both one and 4.5 months of age. Other fat depots such as the axillary and inguinal white adipose tissue and the interscapular brown adipose tissue, however, were comparable between the genotypes. Hepatosplenomegaly contributed to the similar body weights until the age of 9 months when the Glmp gt/gt siblings had significantly reduced body weight. The reduced sizes of the epididymal fat pads were reflected in lower levels of circulating triacylglycerol (TAG) and non-esterified fatty acids (NEFA) in Glmp gt/gt mice. In addition, the Glmp gt/gt mice had lower blood glucose concentration. Gene expression analysis using liver mRNA from WT and Glmp gt/gt mice indicated changes in both glucose and lipid metabolic pathways, and biochemical analysis of whole liver homogenates detected higher TAG levels in Glmp gt/gt liver. Exposing isolated primary hepatocytes from WT and Glmp gt/gt mice to radiolabelled oleic acid (OA) showed that the Glmp gt/gt hepatocytes accumulated significantly more OA than WT hepatocytes, and that the increased OA taken up was stored as TAG. Exposure to radiolabelled glucose and acetate revealed a higher oxidation of glucose and increased de novo lipogenesis, respectively, in Glmp gt/gt hepatocytes compared to WT cells.
In most lysosomal disorders, the primary lysosomal dysfunction induces secondary alterations in other metabolic pathways [25], some of which may be adaptive changes in order to provide metabolites for de novo synthesis of macromolecules, because lysosomal dysfunction might inhibit adequate recycling of metabolites [14,26]. As a consequence, reduced adiposity and body weight, possibly caused by higher tissue demand for metabolites, has been observed in several mouse models with lysosomal disorders [14,26]. However, the body weight of younger Glmp gt/gt mice was comparable to that of their WT siblings since the reduced adiposity was compensated by hepatosplenomegaly. Similar observations have been reported for the mouse models for mucopolysaccharidosis (MPS) type I and IIIB [14]. Interestingly, as seen in the Glmp gt/gt mouse, reduced adiposity, reduced blood glucose, reduced lipid levels and hepatomegaly were also reported in these mice [14]. A similar feed efficiency between WT and Glmp gt/gt mice suggested that the Glmp gt/gt mice did not suffer from malabsorption as was also shown for mouse models with other lysosome deficiencies [14].
We have recently established that the Glmp gt/gt mice suffer from a mild chronic liver injury, as indicated by the modest increase in serum transaminase levels. However, by the age of 6 months, the sustained liver injury led to a well-established fibrosis with increased inflammation and oxidative stress [5], conditions known to disturb the liver's capacity for regulating glucose, lipid and protein homeostasis [18]. As the liver is an important organ for glucose homeostasis [27], the small decrease in resting blood glucose may be caused by increased glucose flow to the liver. Somewhat conflicting studies have been reported regarding glucose uptake capacity in fibrotic liver, which has been ascribed to differences in experimental setup [28][29][30][31][32]. A recent study using primary hepatocytes isolated from early, and advanced fibrotic rat livers, demonstrated a gradual decrease in mitochondrial function [33], an established secondary effect of advanced liver fibrosis [34]. Hepatocytes from early fibrotic livers increased the glycolytic flux in order to compensate for impaired ATP-production by oxidative phosphorylation [33]. Although the ATP-production capacity of Glmp gt/gt mitochondria needs to be further elucidated, we showed by using radiolabelled glucose that the Glmp gt/gt hepatocytes consumed significantly higher levels of glucose compared to WT hepatocytes. Increased flow of glucose to the liver is known to stimulate the expression of lipogenic genes [35]. By using radiolabelled acetate, we showed that de novo lipogenesis was induced in Glmp gt/gt hepatocytes, an expected result given the increased expression of lipogenic genes in Glmp gt/gt liver.
Unexpectedly, the expression of Pdk4 was significantly increased in Glmp gt/gt liver, suggesting an inhibition of the pyruvate dehydrogenase complex, an event usually associated with inhibition of de novo lipogenesis and activation of gluconeogenesis [36]. An increase in Pdk4 expression has been reported in two independent mouse models of liver fibrosis, resulting from chemical-induced liver damage [37] and chronic biliary injury [38]. Interestingly, the increased Pdk4 expression in the chemical-induced model was not accompanied by increased expression of gluconeogenic genes [37]. Similarily, the Mdr2 -/mouse liver (model for chronic biliary injury [39]) had increased expression of lipogenic genes, and developed steatotic nodules [38]. In both studies, the increased Pdk4 expression was explained as preventive adaptations to the hepatic injury [37,38]. Increased Pdk4 expression in the Glmp gt/gt liver is likely to be an adaptive response to the chronic liver injury, although increased glucose flux through the pentose phosphate pathway, which contributes to the antioxidant defense, and NADPH production required for de novo lipogenesis [40] is also a possibility.
Abnormal accumulation of lipids in the liver is a known consequence of dysregulation of metabolism [41]. However, in our initial report, histological analysis failed to reveal obvious steatosis in Glmp gt/gt liver [5]. Here, using a biochemical approach, we showed that Glmp gt/gt mice accumulated slightly more liver TAG than WT animals. The small, relative difference might be undetectable using histological methods. In support of the elevated TAG accumulation in Glmp gt/gt liver, the increased expression of PPARγ as seen in the Glmp gt/gt liver is a hallmark of hepatic steatosis [42], as it stimulates expression of lipogenic genes [18,43] and the fatty acid transporter, CD36 [44]. Increased Cd36 mRNA expression has been found to correlate with increased hepatic TAG content in different models of hepatic steatosis [45][46][47]. After exposure to radiolabelled OA, an increased fatty acid uptake concomitant with increased storage as TAG in Glmp gt/gt hepatocytes was observed, supporting the observed TAG accumulation in Glmp gt/gt liver. Apart from increased fatty acid uptake by hepatocytes and de novo lipogenesis, compromised assembly and secretion of VLDL particles can contribute to lipid accumulation [18,41,48,49]. In our experimental setup, no significant decrease of TAG secretion was detected for Glmp gt/gt hepatocytes. The increased expression of Apoc3, as detected in Glmp gt/gt liver is probably a result of decreased PPARα expression and increased influx of glucose [50]. Apoc3 expression is usually positively correlated with plasma TAG levels [51,52]. However, ApoC3-containing lipoprotein secretion is stimulated by elevated levels of plasma NEFA [53], which were decreased in Glmp gt/gt mice.
The detected liver steatosis in Glmp gt/gt mice may have been promoted by chronic inflammation [54,55]. In our previous study, increased expression of inflammatory cytokines, including tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) were detected in Glmp gt/gt liver [5]. Kupffer cells, activated by liver injury, have been shown to be essential for the development of diet-induced hepatic steatosis in rats, as they alter metabolic pathways in hepatocytes through TNFα secretion [56]. TNFα promotes the lipogenic inducer sterol regulatory element binding protein-1c (SREBP1c) [57] and the protein expression of CD36 [58]. In addition, TNFα stimulates lipolysis in peripheral adipose tissue to release free fatty acids into the circulation [59]. The reduced adipose tissue size and reduced levels of circulating fatty acids observed in Glmp gt/gt mice may be due to prolonged stimulation of adipose tissue lipolysis. Finally, activated Kupffer cells secrete IL-1β, which downregulates the expression of PPARα [60], a positive regulator of lipid catabolism [61].
The recent identification of a lysosomal nutrient sensing machinery (LYNUS) has provided a direct link between intralysosomal nutrient levels and the expression of metabolic genes [62,63]. In periods of nutrient scarcity, LYNUS releases the transcription factor EB into the nucleus where it promotes the expression of genes involved in autophagy and lysosomal biogenesis, in addition to genes involved in fatty acid β-oxidation through induced expression of PPARα and PGC1α [63][64][65]. A significant decrease in Ppara expression was detected in Glmp gt/gt liver, and we might hypothesize that ablation of the lysosomal membrane protein, GLMP, influences normal LYNUS function, a secondary effect observed in many lysosomal disorders [11], thus affecting normal Ppara expression and lipid turnover. Dysregulation of metabolism in Glmp gt/gt liver might in turn affect adipose tissue. However, one of the limitations of the present study is the inability to dismiss the metabolic alterations in Glmp gt/gt liver as secondary effects. We are currently establishing a cell-type-specific transgenic mouse model in order to address this question in future studies.
In summary, we showed that Glmp gt/gt mice have a similar body weight gain and feed efficiency as WT mice until 9 months of age. Similar to some other mouse models with a dysfunctional lysosomal protein, a reduced adiposity and an liver fibrosis were also detected in Glmp gt/gt mice [5]. Analysis of serum glucose and lipid levels showed a significant decrease in Glmp gt/gt mice. In addition to increased hepatic TAG content and changes in the expression of metabolic genes in Glmp gt/gt liver, our data strongly indicate metabolic dysregulation in Glmp gt/gt mice. Analysis using primary hepatocytes supported the findings in Glmp gt/gt liver, and showed enhanced uptake of fatty acids, increased de novo lipogenesis, and higher consumption of glucose in Glmp gt/gt hepatocytes. Ablation of the lysosomal membrane protein GLMP has recently been shown to cause chronic liver injury in mice [5]. In this study, we demonstrated that metabolic dysregulation is a likely contributor to the pathophysiology following GLMP ablation.
Supporting Information S1 Fig. Verification of disrupted GLMP expression in Glmp gt/gt mice. Lysosome-enriched fractions from mouse kidney and liver after tyloxapol treatment were used to verify the ablation of GLMP expression in Glmp gt/gt mice. LAMP1 served as loading control. (TIF) S1 Table. Primers used in qPCR. (DOC)